Humacyte, Inc.

27 Days Left

Class Action Period:
May 10, 2024 - October 17, 2024

Lead Plaintiff Deadline:
January 17, 2025

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

The filed complaint alleges that Humacyte, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) the FDA’s review of the biologics license application would be delayed while Humacyte remediated these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of acellular tissue engineered vessel for vascular trauma; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Humacyte, Inc. purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Humacyte, Inc. during the relevant time frame, you have until January 17, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.